ClinicalTrials.gg
Not yet recruitingNCT05790044Updated Aug 22, 2023

Clonidine for Infra-orbital Nerve Block During Pediatric Cleft Lip Revision Surgeries

An interventional study of Bupivacaine and Clonidine in Postoperative Pain, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Year to 7 Years. Per ClinicalTrials.gov, last updated 2023-08-22.

Sponsored by Assiut University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
1 Year to 7 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 362 studies testing bupivacaine in Pain, Postoperative — 55 open to participants now, 58 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Planned enrollment
144th of 362
86 · median 70
Started
2023
with 15 others
No phase
109 of 362
24 open now
Primary completion
2024-10
later than 7 of 57 live
Registered
264th of 362
by date
Lead sponsor
11 of 362
Assiut University

Among the 362 studies testing bupivacaine in Pain, Postoperative, this one is the 144th largest by planned enrollment, is one of 16 that started in 2023, is one of 109 with no phase, reaches primary completion later than 7 of the 57 other live ones, and was the 264th registered.

By phase

362 studies; the count open now beside each. This study's row is marked.

Phase 4133 · 18 open
No phasethis study109 · 24 open
Phase 243 · 4 open
Phase 342 · 2 open
Phase 121 · 4 open
Phase 2/311 · 3 open
Phase 1/23 · 0 open

By the year they started

First in 2004; this study’s year is marked. 16 started in 2023.

Size and results

Median enrollment 70 across the 362 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.

Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 362 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

Pain in children is usually an undertreated entity. Undertreating perioperative pain could lead to various metabolic, physiologic, and neurophysiological responses. The usual means of management i.e., opioids may increase the incidence of respiratory depression in this age group. Adequate postoperative analgesia in children is a vital part of perioperative care. Good pain relief minimizes oxygen requirement, reduces cardio-respiratory demands, and promotes early ambulation and recovery. Regional block given preoperatively in combination with general anesthesia provides good preemptive analgesia. It is associated with hemodynamic stability, rapid and complete recovery, and reduced analgesic requirement in postoperative period.

Type of the study: A prospective randomized controlled double-blind study.

Read the detailed description

A sample of 86 undergoing cleft lip revision under general anesthesia will be needed. The sample will be randomly divided into two equal groups: Group-I (n=43) will receive total volume of 1 ml each side.of bupivacaine (0.2%) and Group II (n=43) will receive total volume of 1 ml each side.of bupivacaine (0.2%) and 1 µ/kg of clonidine.

2.4.4 -Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...): Preoperative assessment: The day prior to surgery, all patients will undergo pre-anesthetic check-up including detailed history, physical, systemic examination, and weight of the patient. All patients will be investigated for exclusion of any of the above-mentioned contraindications. Laboratory work needed will include Complete Blood Count (CBC); Prothrombin Time and Concentration (PT\& PC). All children will be kept nil per mouth 6-8 h for solids and 2 h for clear liquids. No pre-medications will be given for the purpose of the study. Preparation of the patient: Written consent from parents and emergency resuscitation equipment including airway devices, pediatric advanced life support drugs will be available. Intervention: Patients will be randomly allocated into two groups of 43 patients each: Group C: Children will receive intra-oral infra-orbital nerve block using bupivacaine 0.2% after induction of general anesthesia and before starting surgical procedure. Total volume of 1 ml each side. Group B: Children will receive intra-oral infra-orbital nerve block using bupivacaine 0.2% and clonidine 1 ug/kg after induction of general anesthesia and before starting surgical procedure. Total volume of 1 ml each side.

All patients in this study will be anesthetized by the same team of anesthesiologists and operated upon by the same surgical team who will be unaware of the study medications. General anesthesia (GA) will be standardized for all patients in both groups using 100% O2 with fresh gas flow of 6 L/min and sevoflurane with increments of 1 MAC at each breath up to 8 MAC with appropriate size face mask. Parents will be allowed to be present and collaborated during face mask induction and then leave the theater when their children close their eyes. Intraoperative monitoring will include ECG, pulse oximetry, non-invasive blood pressure, capnography, and temperature. After intravenous access securing, infusion of normal saline 0.9% solution 4 ml/ kg/h starts followed by standard fluid maintenance therapy according to the patient's weight. Endotracheal intubation (RAE-ETT) with appropriate size to the patient's age will be performed after administration of 2 mg/kg propofol. After orotracheal intubation, assisted mechanical ventilation using Ayre's T- piece will be used to maintain end-tidal carbon dioxide at 35±5 mmHg. GA will be maintained with 2-3 MAC sevoflurane. Intravenous dexamethasone 0.25 mg/kg (up to a maximum of 8 mg) will be administered as prophylactic antiemetic.

For intraoral approach of infraorbital nerve block, the patient will be placed in the supine position so that the maxillary occlusal plane forms a 45-degree angle with the floor. A cotton-tipped applicator will be used to apply a topical anesthetic to the oral mucosa of the gum line above the maxillary canine. The infraorbital foramen can be approximated by having a patient look straight ahead and imagining a line down from the pupil to the inferior border of the infraorbital ridge, bicuspid teeth, and mental foramen. The inferior orbital rim will be found with the index and middle fingers of the non-injecting hand. Once it is located, the palpating finger will remain in place to prevent losing landmarks and stop the needle from entering the orbit. The cheek will be retracted with the thumb of the non-injecting hand and then the needle will be into the mucosa above the upper second bicuspid approximately 0.5 cm from the buccal surface. The needle should be directed superiority and remain parallel to the second bicuspid until it is palpated near the foramen. Before injecting the anesthetic, it is important to aspirate to ensure the needle is not within a vessel. The anesthetic will be injected into the space. It is important to avoid injecting the anesthetic into the foramen by keeping firm pressure on the inferior orbital rim with the palpating finger. Immediate complications related to regional anesthesia will be recorded: > Systemic toxicity related to local anesthetics (seizures, heart rhythm, or conduction disorder) > Bleeding at puncture site > Pupil alteration and ocular lesion Mean arterial blood pressure (MAP), heart rate (HR), arterial oxygen saturation (SpO2), and temperature will be recorded before induction of anesthesia. After endotracheal intubation, MAP, HR, SpO2, end-tidal CO2, and temperature will be measured 5 minutes and every 15 minutes until full recovery from the general anesthesia then every 15 min in the PACU for 30 minutes.

Skin incision will be made 20 minutes after infra-orbital block. An increase in HR and MAP above 20% of baseline values with skin incision will be considered as a sign of inadequate analgesia. In this case, fentanyl 1 µg/kg will be given intravenously, and the case will be excluded from the study.

Before the end of surgery, IV paracetamol 15 mg/kg will be administered. After completion of the surgical procedure, sevoflurane administration will be discontinued, and the fresh gas flow will be increased to 8 L/min with 100% oxygen. The patient will be extubated after ensuring adequate orogastric suction and patients will be transferred directly to the post anesthesia care unit (PACU) where parents are allowed to stay with their children in a quiet and warm environment without any stimulus.

The quality of analgesia will be assessed in the PACU immediately postoperatively and then at 4, 8, 12, 16, 20 and 24 hours using FLACC pain scale. The scale has five criteria that are each assigned a score of 0, 1, or 2. The scale is scored in a range of 0-10, with 0 representing no pain while 10 is the worst pain. The results of FLACC scale were interpreted as follows: 0 = Relaxed and Comfortable; 1-3 = Mild discomfort; 4-6 = Moderate pain; 7-10 = Severe pain or discomfort or both. For postoperative pain control paracetamol intravenous infusion 15 mg/kg will be given if the recorded FLACC pain score is 4 or more. Pain scores will be recorded every 10 minutes after administration of rescue analgesia to evaluate pain relief or need for further rescue analgesia. The number of children who will need postoperative rescue analgesics and the duration of analgesia that will be taken at the time when an analgesic is required will be recorded.

Postoperative vomiting episodes will be recorded and treated with intravenous ondansetron 0.1 mg/kg. Postoperative sedation will be assessed using sedation score (1. Awake and alert. 2. Sleeping but easily arouses to voice or light touch. 3. Arouses to loud voice or shaking. 4. Arouses with painful stimuli only. 5. Unarousable). Delayed complications of the blocks will be also investigated and recorded as hematoma, restricted mouth opening, vision, sensory or motor deficit, eating disorder, and local infection.

Parents will be asked to evaluate their satisfaction regarding pain control at the end of 24 h postoperatively through 5point Likert scale (1 = very satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied, 5 = very dissatisfied). Patients will be discharged from the hospital when they are pain free and there is no other medical reason to admit them to a surgical ward.

03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
1 Year to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 1-7 years old.
  • Gender: both.
  • I-II
  • Children scheduled to undergo cleft lip revision surgeries.

Exclusion criteria

Exclusion Criteria:

  • History of developmental delay or mental retardation, which will make observational pain intensity assessment difficult.
  • Parents refusal.
  • to any local anesthetics.
  • Bleeding diathesis.
  • Children with co-morbid conditions like congenital heart disease, respiratory pathology and central nervous system disorders.
  • Skin lesions or wounds at the puncture site of the proposed block.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Active comparator
    Group Placebo

    Children will receive intra-oral infra-orbital nerve block using bupivacaine 0.2% after induction of general anesthesia and before starting surgical procedure. Total volume of 1 ml each side.

    Drug: Bupivacaine

  • Active comparator
    Group Clonidine

    Children will receive intra-oral infra-orbital nerve block using bupivacaine 0.2% and clonidine 1 ug/kg after induction of general anesthesia and before starting surgical procedure. Total volume of 1 ml each side.

    Drug: Clonidine

Interventions

  • intra-oral infra-orbital nerve block with bupivacaine alone

  • intra-oral infra-orbital nerve block with bupivacaine and clonidine

06

What researchers measure

Primary outcomes

  1. Pain score

    FLACC pain score as 1-3 = Mild discomfort; 4-6 = Moderate pain; 7-10 = Severe pain

    Time frame: 24 hours

Secondary outcomes

  1. Heart Rate

    Intraoperative heart rate monitoring

    Time frame: 2 hours

  2. Sedation Score

    1. Awake and alert. 2. Sleeping but easily arouses to voice or light touch. 3. Arouses to loud voice or shaking. 4. Arouses with painful stimuli only. 5. Unarousable

    Time frame: 6 hours

  3. rescue analgesia

    Total rescue doses of paracetamol IV over 24 hours postoperatively used in each group.

    Time frame: 24 hours

  4. 5-point Likert scale Satisfaction Score

    1 = very satisfied, 2 = satisfied, 3 = neither satisfied nor dissatisfied, 4 = dissatisfied, 5 = very dissatisfied

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05790044
Lead sponsor
Assiut University
Responsible party
RAGAA AHMED HERDAN (professor, Assiut University) — Principal investigator
First posted
Mar 29, 2023
Start date
Oct 1, 2023 (estimated)
Primary completion
Oct 1, 2024 (estimated)
Completion
Mar 1, 2025 (estimated)
Last update
Aug 22, 2023

Study contacts

Ragaa Herdan, assis prof
Contact
ragaanesthesia@yahoo.com
01001741748
Hany Ibrahem, professor
Contact
elmorabaa@yahoo.com
01005203980
Ragaa Herdan, professor
principal investigator · faculty of medicine assiut university egypt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupivacaine · Clonidine

Start the discussion